Study summary
A new potassium-channel pill cut focal seizures by about half
53.2%median drop in monthly seizures with 25 mg, vs 10.4% with placebo
What was tested
Azetukalner, a once-daily pill that opens Kv7 potassium channels to calm overactive nerve cells, or placebo added to existing medicines for 12 weeks in adults with focal seizures who had tried a median of 5 earlier medicines.
What they found
- Monthly focal seizures fell by a median 53.2% with 25 mg and 34.5% with 15 mg vs 10.4% with placebo.
- No dose build-up was needed; side effects matched the earlier trial.
What it means
Likely to be submitted for approval as the first drug in a new class for focal epilepsy.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.